US Vaccine Train Won’t be Derailed, Warp Speed Leader Says

November 23, 2020by Elizabeth Dexheimer, Bloomberg News (TNS)
US Vaccine Train Won’t be Derailed, Warp Speed Leader Says

Efforts to speedily develop and distribute a coronavirus vaccine in the U.S. won’t be derailed by a change in administration, said the head of Operation Warp Speed, the federal government’s program aimed at accelerating a COVID-19 jab.

“All decisions are made, the train is running. Whether one administration or the other doesn’t, frankly, make a difference,” Moncef Slaoui said on NBC’s “Meet the Press.”

The operation “has been isolated from the administration, from the political environment, and the political context,” said Slaoui, a former head of GlaxoSmithKline’s vaccines operation.

Yet information on the program hasn’t been shared with the incoming Biden administration, he said, consistent with President Donald Trump’s failure to acknowledge his election loss.

“I have been informed that I should not be saying anything that’s confidential to anybody, including, you know, anybody that’s not part of the administration, and therefore, I’ll act according to what the legal requirements are.”

Surging COVID-19 infections and renewed lockdowns are causing renewed angst across the country. While an effective vaccine is expected to be widely distributed in 2021, there are still a number of hurdles before it can be widely distributed. Pfizer Inc. and BioNTech SE have requested emergency authorization of their vaccine, but it could take at least three weeks for a U.S. Food and Drug Administration decision to move forward.

The U.S. reported 1,870 fatalities on Friday, in a week in which the death rate rapidly rose, according to data compiled by Johns Hopkins University and Bloomberg News.

The daily average of deaths over the past week is now 1,440, compared with 1,177 the week before. That’s the highest level since last spring, when the outbreak in New York and the northeast pushed fatalities to a daily peak of more than 2,600 in late April.

As the virus rages on, hospitals are filling up across the country. Even in the best case scenario of a timely vaccine approval, state governments will struggle to get the rampaging virus under control. And they must do so amid a chaotic transfer of presidential power and a lack of clear policy guidance. Making matters more challenging is the lack of confidence many Americans have in the safety of a vaccine.

Only about half of adults say they would get a COVID-19 vaccine if one were available, according to a September survey from the Pew Research Center.

The U.S. Centers for Disease Control and Advisory Committee on Immunization Practices will issue recommendations on which segments of the population should receive the vaccine first, Slaoui said on NBC.

With 24 hours of an approval of a vaccine, the jabs “will be moving and located in the areas where each state will have told us where they want the vaccine doses,” he said.

___

(c)2020 Bloomberg News

Distributed by Tribune Content Agency, LLC

_____

A+
a-
  • coronavirus vaccine
  • Moncef Slaoui
  • In The News

    Health

    Voting

    Health

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    March 26, 2024
    by Dan McCue
    Consumers Warned to Avoid Certain Topical Pain Relief Products 

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed... Read More

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed for topical use before, during or after certain cosmetic procedures. The warning came after the agency issued warning letters to six companies for marketing these products... Read More

    News From The Well
    scroll top